Invega
- Prescription status not stated
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Paliperidone
- Made by
- Janssen-Cilag International NV
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older. Invega is indicated for the treatment of schizoaffective disorder in adults.
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (PALIPERIDONE). It describes the substance, not this exact product.
Paliperidone is the major active metabolite of risperidone.
The mechanism of action of paliperidone in schizophrenia is unclear.
Metabolism and Elimination Although in vitro studies suggested a role for CYP2D6 and CYP3A4 in the metabolism of paliperidone, in vivo results indicate that these isozymes play a limited role in the overall elimination of paliperidone [see Drug Interactions (7) ].
One week following administration of a single oral dose of 1 mg immediate-release 14 C-paliperidone to 5 healthy volunteers, 59% (range 51% - 67%) of the dose was excreted unchanged into urine, 32% (26% - 41%) of the dose was recovered as metabolites, and 6% - 12% of the dose was not recovered.
Administration of a 12 mg paliperidone extended-release tablet to healthy ambulatory subjects with a standard high-fat/high-caloric meal gave mean C max and AUC values of paliperidone that were increased by 60% and 54%, respectively, compared with administration under fasting conditions.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-28
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Janssen-Cilag International NV |
|---|---|
| Active substance | Paliperidone |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Classification | N05AX13 · Pain, sleep, mood, epilepsy and the brain |
| Authorised on | 2007-06-24 |
| Last updated by the regulator | 2024-07-12 |
| EMA product number | EMEA/H/C/000746 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.